Follow the Kyverna Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €505.3m. The latest transaction was filed on 29 May 2026 (Attribution). Among the most active insiders: Cohen Fred E. Every trade is free.
29
Insider Decl.
n/a
Thresholds
€2m
2 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kyverna Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$30.40.
38Σ signal
Buys €2mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Kyverna Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para enfermedades autoinmunes. Se especializa en la utilización de tecnología de células T para abordar estas afecciones.